HTDS Hard To Treat Diseases Inc (CE)

SHENZHEN, China, March 11 /PRNewswire-FirstCall/ -- Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its subsidiary Mellow Hope announce that the company received Registration Certificate for its MEVAC-Vari vaccine in Guatemala. This is the first Final Approval for HTDS' Varicella vaccine in South America. In general, doctors regard Varicella, commonly known as chickenpox, as a mild viral illness. However, approx. 1 in 50 cases chickenpox associates with complications such as pneumonia and encephalitis, and both diseases report high mortality rate. A source close to HTDS said, "Varicella complications can be averted by a simple vaccination, and we are happy that we obtained the Registration Certificate for our Freeze-dried Varicella vaccine (Mevac-Vari) in Guatemala. As it is Mellow Hope's first Final Approval in South America, we see it as an important step and a very good start for our Varicella vaccine on the South American market. South America offers great potential for our affordable vaccines and our representatives continue their work to deliver Mellow Hope's vaccines to the developing world." In other company news the HTDS management has learned that on line brokerage Scottrade has lifted restrictions for on line buys on HTDS as the oversold issue is being resolved. The company expects other online brokerages to shortly follow similarly. The company reminds our shareholders and followers to monitor PinkSheets.com Filing Section and also our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/. Non-newsworthy events are not press released however posted on these two separate support sites to keep our followers advised of day-to-day events. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link http://www.minamargroup.net/helpdesk. Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas, where amongst other things they continuously spread false rumors, dark propaganda and innuendos in order to manipulate the trading patterns and thwart company plans for their own "quick profits" and self serving needs. The company and its supporters are monitoring these activities and those are promptly being reported on the http://www.stockbasher.com/ website. Visit http://www.stockbasher.com/ and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and other media that provide safe refuge to these individuals and the remedies available to you as an individual investor. Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support Section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at http://www.minamargroup.com/updates. Safe Harbor Statement Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact http://www.minamargroup.com/helpdesk DATASOURCE: Hard to Treat Diseases CONTACT: For medical and scientific dialogue inquiry only, pleasecontact medicalinfo@htdsmedical.com; For any corporate matters, please contacthttp://www.minamargroup.com/helpdesk

Copyright